Onconetix, Inc. cash flow to debt ratio of -19.84K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Onconetix, Inc.'s free cash flow has increased -8.04% from $-10.52M last year to $-9.68M, signaling increasing performance

Onconetix, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability.

Onconetix, Inc.'s debt has decreased relative to shareholder equity from 0.98 last year to 0.02 today, signaling strengthened financials

Onconetix, Inc. has a net cash position, so leverage is healthy.

Onconetix, Inc.'s interest coverage ratio is -12.81, which means that the company struggles to meet interest obligations, signaling financial risk.

Onconetix, Inc.'s profit margin has increased (-43.25%) in the last year from -2.33K% to -1.32K%, signaling increasing performance

Onconetix, Inc.'s short-term liabilities of $9.14M exceed its short-term assets of $6.07M, signaling financial risk

Onconetix, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Onconetix, Inc.'s return on equity of -105.46%, is lower than 15.00%, indicating bad performance

Onconetix, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Onconetix, Inc. has insufficient public price history to evaluate earnings stability.

Onconetix, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Onconetix, Inc. has negative free cash flow, indicating cash burn

Onconetix, Inc.'s yearly earnings has increased -76.09% since last year from $-58.69M to $-14.03M, signaling increasing performance

Onconetix, Inc.'s yearly revenue has decreased 67.70% since last year from $2.52M to $815.37K, signaling decreasing performance

ROIC -56.35% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Onconetix, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Onconetix, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Onconetix, Inc. has insufficient public price history to evaluate ROE consistency.

Onconetix, Inc. has insufficient data to evaluate this check.

Onconetix, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Onconetix, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Onconetix, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Onconetix, Inc. has insufficient data to evaluate this check.

Onconetix, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Onconetix, Inc. has a price-to-book ratio of 0.05x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Onconetix, Inc. has a price-to-sales ratio of 0.77x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue